LifeStance Health Group (NASDAQ:LFST) Cut to Hold at Wall Street Zen

LifeStance Health Group (NASDAQ:LFST) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

Other research analysts have also issued research reports about the company. Barclays started coverage on LifeStance Health Group in a report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price target on the stock. Zacks Research lowered LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. UBS Group increased their target price on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 7th. BTIG Research boosted their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $8.83.

LifeStance Health Group Price Performance

LifeStance Health Group stock opened at $7.07 on Friday. The company has a market capitalization of $2.75 billion, a PE ratio of -235.67 and a beta of 1.12. LifeStance Health Group has a 12-month low of $3.74 and a 12-month high of $8.30. The firm’s fifty day moving average is $6.97 and its 200 day moving average is $5.80. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The business had revenue of $363.81 million during the quarter, compared to analysts’ expectations of $355.06 million. During the same period last year, the company posted ($0.02) earnings per share. The business’s quarterly revenue was up 16.3% on a year-over-year basis. As a group, sell-side analysts predict that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, insider Lisa K. Miller sold 57,240 shares of the firm’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $6.43, for a total transaction of $368,053.20. Following the transaction, the insider directly owned 261,292 shares in the company, valued at approximately $1,680,107.56. This trade represents a 17.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert Bessler sold 119,942 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68. Following the completion of the sale, the director owned 1,318,983 shares of the company’s stock, valued at approximately $9,285,640.32. The trade was a 8.34% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 327,326 shares of company stock valued at $2,259,317. 3.20% of the stock is owned by insiders.

Institutional Investors Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in LFST. Vanguard Group Inc. boosted its stake in shares of LifeStance Health Group by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock worth $124,608,000 after buying an additional 3,086,506 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in LifeStance Health Group by 27.2% during the third quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock worth $45,998,000 after acquiring an additional 1,790,694 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in LifeStance Health Group by 62.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after acquiring an additional 1,839,465 shares during the period. Barclays PLC boosted its position in LifeStance Health Group by 74.7% in the third quarter. Barclays PLC now owns 3,508,552 shares of the company’s stock worth $19,297,000 after purchasing an additional 1,499,687 shares during the last quarter. Finally, AustralianSuper Pty Ltd bought a new position in LifeStance Health Group in the 3rd quarter valued at $17,056,000. Hedge funds and other institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.